close modal

How Can We Help You?

Accent Lines

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Kaleo Logo

News

Media Contact

Caryn Foster Durham
Senior Director, Corporate Communications
(804) 256-7766
media.inquiries@kaleo.com

Woman walking in hallway
Media Contact

Caryn Foster Durham
Senior Director, Corporate Communications
(804) 256-7766
media.inquiries@kaleo.com

News Archive

Accent Lines
October 25, 2022

Kaléo Announces Appointment of Major General Elder Granger, M.D., to Board 
September 27, 2022

Kaléo Adds Chief Business Officer to Executive Team
September 21, 2022

Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
September 13, 2022

Rapid Opioid Countermeasure System Product Team Wins Award for Outstanding Program Management Team at 2022 Military Health System Research Symposium
August 11, 2022

Kaléo Announces Executive Appointments and New Government Business Unit 
August 2, 2022

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)
May 8, 2022

Caring for the Caregiver
March 2, 2022

FDA Approves Kaléo’s Naloxone Auto-Injector 10 mg for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids
November 29, 2021

Marathon Asset Management Announces Acquisition of Kaléo
December 21, 2020

Kaléo Expands Executive Team with New Appointments
August 18, 2020

The Upcoming School Year is Expected to be Fraught with Uncertainty, Particularly for Children with Life-Threatening Food Allergies
August 10, 2020

Kaléo and the pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® (epinephrine injection, USP) Auto-Injector for the Treatment of Serious Allergic Reactions Across Canadian Provinces
August 10, 2020

Kaléo et l’Alliance pancanadienne pharmaceutique (APP) concluent leurs négociations sur l’auto-injecteur ALLERJECT® (épinéphrine injectable, USP) destiné au traitement des réactions allergiques graves dans les différentes provinces canadiennes.
May 12, 2020

Kaléo Announces ALLERJECT® (epinephrine injection, USP) Auto-Injector Will Be Available for Canadians at Risk for Anaphylaxis Starting May 19, 2020
May 12, 2020

Kaléo annonce qu’à partir du 19 mai 2020 l’auto-injecteur ALLERJECT® (épinéphrine injectable, USP) sera à la disposition des Canadiens à risque d’anaphylaxie.
July 11, 2019

Walgreens and Kaléo Expand Retail Pharmacy Collaboration to Include AUVI-q® (epinephrine injection, USP) 0.1 mg, the Only FDA-Approved Epinephrine Auto-Injector for Infants and Toddlers, 16.5 – 33 lbs
December 12, 2018

Authorized Generic for EVZIO® (naloxone HCl injection) to be Available at a Reduced List Price of $178
September 6, 2018

Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues, Providing Patients Access to AUVI-Q® (epinephrine injection, USP) Through Walgreens Locations Nationwide
1 2 3